Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (February 2022)
35 slides from Arovella Therapeutics's investor presentation, Feb 1, 2022
Slide 1: Investor Presentation
ASX: ALA Investor Presentation Dr Michael Baker February 2022
Slide 2: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In prepa
Slide 3: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights World Leading Partners Allogeneic Platform, Two Targets Acquiring New Technologies Arovella licenced its iNKT Cell Therapy Arovella is developing off the shelf cell Arovella continues to focus on sourcing, Platform from Imperial College London and its therapies for C
Slide 4: Recent Milestones
Recent Milestones Arovella enters into Research Agreement with Imperial Plasmid and Lentivirus AUG 2021 manufacturer selected DEC 2021 MTPK terminates Commenced CAR19 ZolpiMist Agreement Arovella selected to Plasmid and Vector AUG 2021 present at Biotech Manufacturing Professor Karadimitris Showcase
Slide 5: Arovella Company Overview
Arovella Company Overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA 40000000 0.08 Market capitalisation1 $24 million 35000000 0.07 Enterprise value $15 million 30000000 Shares on issue1 601 million 0.06 52-week low / high $0.033 / $0.075 25000000 0.05 Cash (30 December 2021)
Slide 6: Arovella Board and Senior Leadership
Arovella Board and Senior Leadership Paul Hopper Dr. Michael Baker Dr. Debora Barton CHAIRMAN CEO & MANAGING DIRECTOR DIRECTOR Over 25 years experience in the medical, Over 15 years experience in scientific Over 20 years of oncology experience, in healthcare & life sciences sectors. Focussed researc
Slide 7: Arovella Therapeutics Pipeline
Arovella Therapeutics Pipeline Cell Therapy INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE2/31 PARTNER ALA-101 CD19 expressing CD19 Expressing Lymphoma (CAR19-iNKT) cancers ALA-102 Not Disclosed ND ALA-103 Not disclosed ND ALA-104 Multiple (DKK1-CAR-iNKT) Myeloma Multiple Myeloma & Solid Tumours Oro
Slide 8: Cell Therapy Commercial Activity
Cell Therapy Commercial Activity Transactions Significant Capital Raises Parties Deal Type Total Value Company Amount Raised Gilead / Kite Acquisition US$11.9b Sana Biotech US$675m Celgene / Juno Acquisition US$9b Lyell US$425m Janssen / Fate Partnership US$3b Legend Biotech US$424m Strategic Carsge
Slide 9: Commercial Activity for iNKT Cell Therapies
Commercial Activity for iNKT Cell Therapies Strategic Acquisition Market Cap Partnership Value US$185m Total3 US$110m2 US$875m Total1 Market Cap Phase 1 Phase 1 Preclinical AU$24m2,4 Preclinical May 2021 – Appia Bio May 2021 – Kuur Oct 2021 – MiNK Jun 2021 – Acquired the raised US$52m in their Thera
Slide 10: iNKT Cell Therapy Platform
iNKT Cell Therapy Platform © Copyright Arovella Therapeutics Ltd 2022
Slide 11: Overview of CAR-iNKT Cell Therapy
Overview of CAR-iNKT Cell Therapy Blood Collection and Immune Cell Harvesting Following blood collection from a healthy donor at a hospital or clinic, immune cells are collected Isolation and re-programming of immune cells Isolated iNKT cells are genetically re-programmed to produce a chimeric a
Slide 12: Expand the Cell Therapy Revolution: iNKT Cells
Expand the Cell Therapy Revolution: iNKT Cells iNKT Cell Benefits They are one of the most potent, naturally occurring immune cells Healthy Donor They bridge the innate and adaptive immune system They naturally target and kill cancer cells They activate other beneficial immune cells They c
Slide 13: CAR-iNKT Cells are Engineered to Enhance Activity
CAR-iNKT Cells are Engineered to Enhance Activity APPROVED CAR-NK CELLS CAR-iNKT CAR-T CELLS CELLS Subpopulation of T cells with NK cell properties Intrinsic anti-cancer receptor (dual targeting) Persistence TBD TBD1 Minimal genetic engineering for off the shelf Naturally suppres
Slide 14: How does the CAR-iNKT Cell Therapy Platform Work?
How does the CAR-iNKT Cell Therapy Platform Work? 1. iNKT cells contain 2. We introduce a 3. CAR-iNKT cells are 4. The cancer cell is an iTCR that chimeric antigen activated after they attach killed, and other naturally assists receptor (CAR) to target to the cancer cells, components are to recognis
Slide 15: ALA-101: CAR19-iNKT Cells to Treat Blood Cancers
ALA-101: CAR19-iNKT Cells to Treat Blood Cancers CAR19-iNKT Outperforms Conventional Therapies ALA-101 is anticipated to be an effective, Faster Killing of Cancer Spontaneous Secondary off-the-shelf cell therapy for the treatment Cells That Have CD1d Remission of CD19 expressing cancers CAR19- iNK
Slide 16: Pipeline Expansion ALA-104
Pipeline Expansion ALA-104 © Copyright Arovella Therapeutics Ltd 2022
Slide 17: Development of DKK1-CAR to Date
Development of DKK1-CAR to Date The DKK1 mAb was developed at MD Anderson and can be incorporated Already Completed Arovella To Complete into a chimeric antigen receptor (CAR) The DKK1 peptide-targeting mAb has demonstrated activity against multiple myeloma and breast cancer The DKK1 peptide-t
Slide 18: DKK1-CAR-T Cell Activity in Multiple Myeloma
DKK1-CAR-T Cell Activity in Multiple Myeloma DKK1-CAR T cells were tested in three different animal models for multiple myeloma, displaying robust activity in all standard models Model 1 – U266 Model 2 – KMS-12-BM Model 3 – MM.1S 100 100 100 S u r v iv a l p e r c e n ta g e S u r v iv a l p e r c e
Slide 19: DKK1-CAR-T Preclinical Safety
DKK1-CAR-T Preclinical Safety Prof Qing Yi at Houston Methodist has demonstrated: • They only kill cells that have the DKK1 peptide presented in an HLA-A2 complex on their surface • They do not kill healthy blood cells • That the DKK1-CAR-T cells are considered safe using in vivo models • The DKK1 m
Slide 20: The Inventor – Professor Qing Yi
The Inventor – Professor Qing Yi Professor Qing Yi is a trained medical immunologist with over 25 years of experience. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers. He has trained at the Karolinska Institute, MD Ande
Slide 21: DKK1’s Role in Cancer
DKK1’s Role in Cancer 2021 2019 2019 2019 2018 DKK1 is overproduced in a number of cancer types, including pancreatic, oesophageal, hepatocellular, breast, lung cancer and multiple myeloma Oncogene, Annals of translational Oncogene, American journal of Clinical & experimental 2021 Jul 01; 40(26) m
Slide 22: Robust Intellectual Property
Robust Intellectual Property Patent life until 2039 As the first DKK1-CAR product, it has a robust patent position Title: Monoclonal Antibodies Against MHC- Bound Human Dickkopf-1 Peptides and Uses Thereof Applicant: Board of Regents, The University of Texas System Patent applications have been file
Slide 23: CAR-iNKT Cell Therapy Development
CAR-iNKT Cell Therapy Development Acquire the license to additional CARs/Technologies complementary to the iNKT cell therapy platform Dose first patient in Phase 1 clinical trial for CD19 producing cancers FDA IND clearance for CAR19-iNKT program Complete GMP manufacturing of CAR19-iNKT cell
Slide 24: CAR-iNKT Cell Manufacturing Pathway
CAR-iNKT Cell Manufacturing Pathway • Plasmid DNA encoding the CAR Key Components • Lentiviral vector to deliver the CAR • iNKT cells to produce the CAR (final product) Prepare plasmid and Lentiviral vector Select manufacturer for the CAR Process Development 1st Scale-up test Master Cell Bank GMP Pl
Slide 25: Thank You
Thank You Dr Michael Baker CEO & Managing Director Email: mbaker@arovella.com Mobile: +61 403 468 187 © Copyright Arovella Therapeutics Ltd 2022
Slide 26: Appendices
Appendices © Copyright Arovella Therapeutics Ltd 2022
Slide 27: Cancer Continues to be a Major Health Issue
Cancer Continues to be a Major Health Issue Worldwide, an estimated Cancer is a leading cause of The global cancer biologics 19.3 million new cancer death worldwide, market should reach $143.0 cases (18.1 million excluding accounting for nearly 10 billion by 2026 from $77.5 nonmelanoma skin cancer))
Slide 28: Chimeric Antigen Receptor (CAR) Cell Therapy Revolution
Chimeric Antigen Receptor (CAR) Cell Therapy Revolution CAR-T Revolution Product Approval Year 2020 Revenue Due to their impressive cure rates, CAR-T cell therapies have revolutionised the treatment of cancer. As of 2017 US$474m1 October 2021, there are five approved CAR-T products to treat a number
Slide 29: What are Chimeric Antigen Receptors (CARs)?
What are Chimeric Antigen Receptors (CARs)? Immune Cell CD19-CAR CAR-Producing Cell Cancer Cell The immune cells are Specific immune cells for Once administered to the genetically re-programmed the therapy are collected cancer patient, the CAR- with a CAR, supercharging from a patient or a producing
Slide 30: Preclinical In Vivo Safety Evaluation of CAR19-iNKT cells
Preclinical In Vivo Safety Evaluation of CAR19-iNKT cells CAR19-iNKT cells do not elicit adverse effects in preclinical mouse tumour models No body weight loss Mice Body Weight Data in mouse models did not show off-target effects No histological changes in normal tissues Beside the profound
Slide 31: iNKT Cells Protect Against Graft Versus Host Disease
iNKT Cells Protect Against Graft Versus Host Disease 2017 2017 2016 2015 2015 Conventional CAR-T cell therapies are limited to autologous products due to the potential for acute graft versus host disease (GVHD) Front Immunol 2017 July 31;8:900 Leukemia 2017 Apr;31(4):903-912 Blood 2016 Apr 7;127(1
Slide 32: Use of iNKT Cells in Clinical Trials
Use of iNKT Cells in Clinical Trials 2020 2017 2013 2012 2011 iNKT cells, in the presence and absence of CARs, have been used in numerous clinical trials against a range of tumour types, including blood cancers and solid tumours Nat Med Clin Cancer Res. Blood J Clin Immunol. Clin Cancer Res. 2020
Slide 33: A Novel Cancer Target – DKK1 (ALA-104)
A Novel Cancer Target – DKK1 (ALA-104) DKK1 is a secreted protein that functions as a negative regulator of the Wnt signaling pathway DKK1 is overproduced in numerous cancer types and DKK1 peptides are loaded onto immune complexes and presented at the surface of cancer cells Our DKK1 mAb/CAR t
Slide 34: Understanding Immunology and Cell Therapy
Understanding Immunology and Cell Therapy Antigen = Any substance that induces the immune system to produce antibodies against it is called an antigen. Any foreign invaders, such as pathogens (bacteria and viruses), chemicals, toxins, and pollens, can be antigens. CAR = Chimeric Antigen Receptor
Slide 35: Committed to helping people live longer and healthier lives
Committed to helping people live longer and healthier lives Patient-Centric It starts with the end in mind. In our case, it is our patients. At Arovella, we are invested in making a positive difference in helping patients live longer and healthier lives. Creating a brighter future for people is our
Arovella Therapeutics — Investor Presentation (February 2022) on 6ix